Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SKYE

Skye Bioscience Inc

Apr 25 • 10:16AM ET

13.00

Dollar change +0.15
Percentage change 1.17	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: HRTS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.70	Insider Own	55.19%	Shs Outstand	28.06M	Perf Week	-23.39%
Market Cap	364.78M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	0.00%	Shs Float	12.58M	Perf Month	-5.59%
Income	-37.64M	PEG	-	EPS next Q	-0.16	Inst Own	9.28%	Short Float	0.37%	Perf Quarter	477.78%
Sales	0.00M	P/S	-	EPS this Y	85.38%	Inst Trans	-	Short Ratio	1.09	Perf Half Y	439.42%
Book/sh	-0.17	P/B	-	EPS next Y	-11.46%	ROA	-357.64%	Short Interest	0.05M	Perf Year	282.35%
Cash/sh	0.37	P/C	35.28	EPS next 5Y	-	ROE	-	52W Range	1.44 - 19.41	Perf YTD	377.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.94%	ROI	-	52W High	-33.02%	Beta	1.75
Dividend TTM	-	Quick Ratio	0.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	802.78%	ATR (14)	1.88
Dividend Ex-Date	-	Current Ratio	0.84	EPS Y/Y TTM	35.07%	Oper. Margin	0.00%	RSI (14)	48.78	Volatility	14.43% 17.16%
Employees	11	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	90.91%	Payout	-	Rel Volume	0.31	Prev Close	12.85
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	42.86K	Price	13.00
SMA20	-3.83%	SMA50	5.49%	SMA200	132.35%	Trades		Volume	2,157	Change	1.17%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Initiated	Oppenheimer	Outperform	$25

Apr-23-24 07:00AM	Skye Bioscience to Present at Upcoming Investment Conferences (GlobeNewswire) -5.27%
Apr-10-24 08:00AM	Skye Bioscience Uplists to The Nasdaq Global Market (GlobeNewswire) +39.69%
Mar-11-24 09:20AM	Skye Bioscience Announces $40 Million Private Placement Equity Financing (Newsfile) -24.95%
Mar-04-24 07:00AM	Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors (GlobeNewswire) +7.59%
Feb-26-24 07:00AM	Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension (GlobeNewswire) +13.82%
07:00AM	Loading…
Feb-07-24 07:00AM	Skye Bioscience to Present at Oppenheimer Investor Conference (Newsfile) -7.55%
Jan-29-24 08:00AM	Skye Bioscience Announces $50.25 Million Private Placement Equity Financing (Newsfile) +29.03%

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include Nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SKYE

Skye Bioscience Inc

Upgrade your FINVIZ experience